Lung Cancer Clinical Trial
Official title:
Whole-Body 18F-Fluorodeoxyglucose Positron Emission Tomography to Measure the Response to Induction Chemotherapy of Potentially Resectable Lung and Esophageal Carcinomas
RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 positron emission tomography
(PET) scans, may improve the ability to detect lung and esophageal cancer or their
recurrence.
PURPOSE: Phase II/III trial to study the effectiveness of fludeoxyglucose F 18 PET scans in
measuring response to induction chemotherapy in patients with esophageal and lung cancer
that may be removed by surgery.
OBJECTIVES: I. Determine whether whole body fludeoxyglucose F 18 (F-18
2-fluoro-2-deoxy-D-glucose; FDG) positron emission tomography (PET) can quantitate the
response to induction (preoperative) chemotherapy in patients with esophageal or non-small
cell lung cancer (NSCLC) by correlating changes in PET scan images with surgical staging,
frequency of complete resection, disease-free survival, and overall survival. II. Correlate
PET scan results with the multiple conventional complementary imaging modalities of thoracic
and/or abdominal CT, bone scans, and cranial MRI. III. Evaluate the use of PET scanning to
uncover disease sites undetected by current imaging modalities.
OUTLINE: This is a nonrandomized study. The choice of chemotherapeutic regimen is at the
discretion of the medical oncologist. If the tumor is resectable after treatment with
chemotherapy, the patients undergoes the appropriate resection as defined by the thoracic
surgeon. All patients have positron emission tomography (PET) scans done within 2 weeks
before the first dose of chemotherapy and again about 2-3 weeks after the third or fourth
dose of chemotherapy. Patients are asked to not eat or drink 6 hours before coming into the
hospital for the PET scan. They are administered an injection of a solution of
fluorodeoxyglucose F 18 (FDG) and then undergo a PET scan.
PROJECTED ACCRUAL: An estimated 75 patients (50 lung cancer and 25 esophageal cancer
patients) will be accrued into this protocol over 24-30 months.
;
Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|